The superior weight loss achieved with semaglutide may reduce the need for additional weight loss interventions, obesity-related medical treatments, or bariatric surgery
Contraindications may include a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis, and other conditions
As a result of semaglutide GLP-1, hormones such as insulin may be balanced out, which may have the effect of curbing appetite and letting people lose weight by eating less
Stratified effect sizes for changes in time in range, HbA1c and weight loss are listed according to category of baseline BMI
By Lauren Arcuri Glucagon-like peptide-1 (GLP-1) receptor agonist drugs such as semaglutide and tirzepatide were originally developed to treat type 2 diabetes
The STEP 1 trial (Wilding et al., NEJM 2021) demonstrated an average 14.9% body weight reduction with semaglutide 2.4mg weekly over 68 weeks, compared to 2.4% with placebo a magnitude of effect that no prior anti-obesity medication had achieved
.png)
